Orexigen Obesity Drug Meets Goals in 3 Studies

SAN DIEGO (AP) -- Orexigen Therapeutics Inc. said Monday that its obesity-drug candidate Contrave met its main goals in three late-stage clinical trials, and also surpassed a Food and Drug Administration requirement for effectiveness. Patients who took Contrave had significantly greater weight loss than those who took a placebo, and the drug also reduced other risk factors like waist circumference, the company said. For diabetes patients, the drug also reduced blood sugar levels. The San...Full Story
Commenting on this article is closed.